Levels of antiangiogenic factors in preeclamptic pregnancies

References

• Ahmad S, Ahmed A. 2004. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 95:884e91.
   Google Scholar
• Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. 2008. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol. 199:266e1–266e6.
   Google Scholar
• Catarino C, Rebelo I, Belo L, Rocha S, Castro EB, Patrício B, Quintanilha A, Santos-Silva A. 2009. Fetal and maternal angiogenic/anti-angiogenic factors in normal and preeclamptic pregnancy. Growth Factors. 27:345–351.
   PubMed Web of Science ®Google Scholar
• Chien PF, Arnott N, Gordon A, Owen P, Khan KS. 2008. How useful is uterine artery Doppler flow velocimetry in the prediction of preeclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG. 107:196–208.
   Google Scholar
• Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. 2008. Maternal death in the 21st century: Causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 199 36: e31–e35.
   Google Scholar
• Gu Y, Lewis DF, Wang Y. 2008. Placental productions and expressions of sEndoglin, sFlt-1, and PlGF in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 93:260–266.
   PubMed Web of Science ®Google Scholar
• Hirashima C, Ohkuchi A, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. 2008. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res. 31:1541–1548.
   PubMed Web of Science ®Google Scholar
• Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A. 2008. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta. 29:555–563.
   PubMed Web of Science ®Google Scholar
• Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. 2009. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn. 29:464–470.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. 2004. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 350:672–683.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEP Study Group. 2006. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 355:992–1005.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 111:649–658.
   PubMed Web of Science ®Google Scholar
• Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH. 2002. Second-trimester uterine artery Doppler screening in unselected populations: A review. J Matern Fetal Neonatal Med. 12:78–88.
   PubMedGoogle Scholar
• Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. 2007. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 50:137–142.
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. 2005. Latest advances in understanding preeclampsia. Science. 308:1592–1594.
   PubMed Web of Science ®Google Scholar
• Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. 1989. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol. 161:1200–1204.
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. 2008. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 21:9–23.
   PubMed Web of Science ®Google Scholar
• Schlembach D, Wallner W, Sengenberger R. 2007. Angiogenic growth factor levels in maternal and fetal blood: Correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol. 29:407–413.
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM. 2005. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: Relationship to circulating placental growth factor. J Clin Endocrinol Metab. 90:4895–4903.
   PubMed Web of Science ®Google Scholar
• Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 5:519–524.
   PubMed Web of Science ®Google Scholar
• Stepan H, Geide A, Faber R. 2004. Soluble fms-like tyrosine kinase 1. N Engl J Med. 351:2241–2242.
   PubMed Web of Science ®Google Scholar
• Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007a; 49:818–824.
   PubMed Web of Science ®Google Scholar
• Stepan H, Kramer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab. 2007b; 92:2831–2834.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 12:642–649.
   PubMed Web of Science ®Google Scholar
• Walther T, Wallukat G, Jank A. 2005. AT1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 46:1275–1279.
   PubMed Web of Science ®Google Scholar